Gland Pharma Appoints Xiao Le As Chief Investment Officer
Gland Pharma Limited appoints Xiao Le as Chief Investment Officer, effective November 9, 2026.
Le has more than 15 years of experience in investment and asset management across medical devices, biopharma, Diagnostics and Tools, and healthcare services. He has a range of roles, including as Chief Financial Officer of MegaRobo Technologies, Singapore; Director on the Board of Directors of CANbridge Pharmaceuticals, United States, representing WuXi; Senior Director of M&A and Strategic Investments for Wuxi AppTec; Director of Dimensions Capital; and various roles in Middleton Gardiner Group, LLC; NYSE; and Bank of America Merrill Lynch.
He holds a bachelor’s degree in Bio-engineering from Johns Hopkins University and a master’s degree in Finance from the Massachusetts Institute of Technology.


